参考文献/References:
[1]Antunes G,Neville E,Duffy J,et al.Pleural Diseases Group, Standards of Care Committee, British Thoracic Society. BTS guidelines for the management of malignant pleural effusions[J].Thorax,2003,58 Suppl 2(Suppl 2):ii29-ii38.[2]Lombardi G,Zustovich F,Nicoletto MO,et al.Diagnosis and treatment of malignant pleural effusion: a systematic literature review and new approaches[J].Am J Clin Oncol,2010,33(4):420-423.[3]Jiang ZY,Qin SK.Study progression of recombinant human endostatin (Endostar) for the treatment of malignant serous effusion[J].Chinese-German J Clin Oncol,2011,10(8):435-441．[4]Lee YC,Wilkosz S.Malignant pleural effusions: fixing the leaky faucet[J].Am J Respir Crit Care Med,2008,178(1):3-5.[5]Koegelenberg CFN,Shaw JA,Irusen EM,et al.Contemporary best practice in the management of malignant pleural effusion[J].Ther Adv Respir Dis,2018,12:1753466618785098.[6]Becker G,Galandi D,Blum HE.Malignant ascites: systematic review and guideline for treatment[J].Eur J Cancer,2006,42(5):589-597.[7]Moon YW,Choi ST,Cho BC,et al.A case of successful intrapleural chemotherapy with Cisplatin plus cytarabine for intractable malignant pleural effusion[J].Yonsei Med J,2007,48(6):1035-1038.[8]Olden AM,Holloway R.Treatment of malignant pleural effusion: PleuRx catheter or talc pleurodesis? A cost-effectiveness analysis[J].J Palliat Med,2010,13(1):59-65.[9]Antunes G,Neville E,Duffy J,et al.Pleural Diseases Group, Standards of Care Committee, British Thoracic Society. BTS guidelines for the management of malignant pleural effusions[J].Thorax,2003,58 Suppl 2(Suppl 2):ii29-ii38.[10]Rahman NM,Davies HE,Salzberg M,et al.Use of lipoteichoic acid-T for pleurodesis in malignant pleural effusion: a phase I toxicity and dose-escalation study[J].Lancet Oncol,2008,9(10):946-952.[11]Li J,Yao H,Lei Y,et al.Establishment of a human intrapleural hyperthermic perfusion model and analysis of pleural malignancy treatment depth[J].Respir Med,2018,138:144-149.[12]Garofalo A,Valle M,Garcia J,et al.Laparoscopic intraperitoneal hyperthermic chemotherapy for palliation of debilitating malignant ascites[J].Eur J Surg Oncol,2006,32(6):682-685.[13]Zhou H,Wu W,Tang X,et al.Effect of hyperthermic intrathoracic chemotherapy (HITHOC) on the malignant pleural effusion: A systematic review and meta-analysis[J].Medicine (Baltimore),2017,96(1):e5532.[14]王超锋,王模伟.胸腔灌注化疗与胸腔循环热灌注化疗对非小细胞肺癌并发胸腔积液的临床疗效比较[J].河南医学研究,2020,29(10):1786-1787.[15]刘玲,钟世寿,李国苗.复方苦参注射液联合顺铂治疗恶性胸腔积液疗效及不良反应观察[J].现代肿瘤医学,2017,25(2):230-232,233.[16]Hu CY,Zhang YH,Wang T,et al.Interleukin-2 reverses CD8(+) T cell exhaustion in clinical malignant pleural effusion of lung cancer[J].Clin Exp Immunol,2016,186(1):106-114.[17]Han L,Jiang Q,Yao W,et al.Thoracic injection of low-dose interleukin-2 as an adjuvant therapy improves the control of the malignant pleural effusions: a systematic review and meta-analysis base on Chinese patients[J].BMC Cancer,2018,18(1):725.[18]Rasolzadeh S,Haji Fatahaliha M,Hosseini M,et al.Recombinant LPG3 Stimulates IFN-Γ and TNF-Α Secretion by Human NK Cells[J].Iran J Parasitol,2015,10(3):457-464.[19]Hong H,Jiang L,Lin Y,et al.TNF-a promotes Iymphangiogenesisand lymphatic metastasisof gallbladder cancer through the ERKI/2/AP-l/VEGF-D pathway[J].BMC cancer,2016,16:240.[20]Basso FG,Pansani TN,Turrioni AP,et al.Tumor Necrosis Factor-α and Interleukin (IL)-1β, IL-6, and IL-8 Impair In Vitro Migration and Induce Apoptosis of Gingival Fibroblasts and Epithelial Cells, Delaying Wound Healing[J].J Periodontol,2016,87(8):990-996.[21]Fu T,Lin Y,Zeng Q,et al.Thoracic perfusion of recombinant mutant human tumor necrosis factor (rmhTNF) can be considered as a good adjunct in the treatment of malignant pleural effusion caused by lung cancer[J].BMC Pulm Med,2020,20(1):175.[22]白晓菊.中药注射剂抗肿瘤品种分析[J].中药药理与临床,2009,25(3):72-73.[23]Marquez-Medina D,Popat S.Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases[J].Clin Transl Oncol,2016,18(8):760-768.[24]Zhang Y,Yu LK,Lu GJ,et al.Prognostic values of VEGF and endostatin with malignant pleural effusions in patients with lung cancer[J].Asian Pac J Cancer Prev,2014,15(19):8435-8440.[25]Fang SC,Zhang HT,Hu HD,et al.Effect of Endostar combined with angiopoietin-2 inhibitor on malignant pleural effusion in mice[J].Med Oncol,2015,32(1):410.[26]Zhao H,Li X,Chen D,et al.Intraperitoneal administration of cisplatin plus bevacizumab for the management of malignant ascites in ovarian epithelial cancer: results of a phase III clinical trial[J].Med Oncol,2015,32(2):292.[27]Chen Y,Mathy NW,Lu H.The role of VEGF in the diagnosis and treatment of malignant pleural effusion in patients with non-small cell lung cancer (Review)[J].Mol Med Rep,2018,17(6):8019-8030.[28]Davidson B,Konstantinovsky S,Nielsen S,et al.Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression[J].Clin Cancer Res,2004,10(21):7335-7346.[29]Hooper CE,Elvers KT,Welsh GI,et al.VEGF and sVEGFR-1 in malignant pleural effusions: association with survival and pleurodesis outcomes[J].Lung Cancer,2012,77(2):443-449.[30]Yang S,Yang C,Yu F,et al.Endoplasmic reticulum resident oxidase ERO1-Lalpha promotes hepatocellular carcinoma metastasis and angiogenesis through the S1PR1/STAT3/VEGF-A pathway[J].Cell Death Dis,2018,9(11):1105.[31]程少先,谭诗云,徐文礼.重组人血管内皮抑素联合奈达铂治疗非小细胞肺癌合并恶性胸腔积液的临床疗效分析[J].实用临床医药杂志,2019,23(13):56-59.[32]王洲飞,许子寒,朱广阔,等.恩度和顺铂治疗原发性肺癌合并恶性胸腔积液的短期疗效对比分析[J].中华肺部疾病杂志（电子版）,2019,12(5)：539-543．[33]秦叔逵,杨柳青,梁军,等.腔内应用重组人血管内皮抑制素和/或顺铂治疗恶性胸腹腔积液的前瞻性、随机对照、全国多中心Ⅲ期临床研究[J].临床肿瘤学杂志,2017,22(3):193-202．[34]Mohajeri A,Sanaei S,Kiafar F,et al.The Challenges of Recombinant Endostatin in Clinical Application: Focus on the Different Expression Systems and Molecular Bioengineering[J].Adv Pharm Bull,2017,7(1):21-34.[35]汪华,赵亚宁,张斌.不同剂量恩度联合顺铂胸腔灌注治疗非小细胞肺癌恶性胸腔积液的临床分析[J].中国医药导报,2017,14(23):88-91,106.[36]Chen D,Song X,Zhang Y,et al.Optimizing intrapleural bevacizumab dosing in non-small-cell lung cancer-mediated malignant pleural effusion: less is more [published correction appears in Future Oncol. 2021 Apr;17(11):1441-1443][J].Future Oncol,2018,14(21):2131-2138.[37]Ma J,Zhang H,Tang K,et al.Tumor-derived microparticles in tumor immunology and immunotherapy[J].Eur J Immunol,2020,50(11):1653-1662.[38]Xu P,Tang K,Ma J,et al.Chemotherapeutic Tumor Microparticles Elicit a Neutrophil Response Targeting Malignant Pleural Effusions[J].Cancer Immunol Res,2020,8(9):1193-1205.[39]Guo M,Wu F,Hu G,et al.Autologous tumor cell-derived microparticle-based targeted chemotherapy in lung cancer patients with malignant pleural effusion[J].Sci Transl Med,2019,11(474):eaat5690.
相似文献/References:
[1]李雪芹,王存德,龚 泉,等.鸦胆子油乳注射液配合恩度治疗恶性胸腔积液的临床分析[J].医学信息,2018,31(03):13.[doi:10.3969/j.issn.1006-1959.2018.03.005]
LI Xue-qin,WANG Cun-de,GONG Quan,et al.Clinical Analysis of Brucea Javanica Oil Emulsion Injection Combined with Endor in the Treatment of Malignant Pleural Effusion[J].Journal of Medical Information,2018,31(03):13.[doi:10.3969/j.issn.1006-1959.2018.03.005]
[2]朱淑娟.多西他赛在控制晚期非小细胞肺癌恶性胸腔积液的
疗效和安全性评估[J].医学信息,2018,31(15):132.[doi:10.3969/j.issn.1006-1959.2018.15.042]
ZHU Shu-juan.Efficacy and Safety of Docetaxel in the Control of Malignant Pleural Effusion in Patients with Advanced Non-small Cell Lung Cancer[J].Journal of Medical Information,2018,31(03):132.[doi:10.3969/j.issn.1006-1959.2018.15.042]
[3]罗 超,葛明建.非小细胞肺癌干性胸膜转移的研究现状[J].医学信息,2021,34(03):31.[doi:10.3969/j.issn.1006-1959.2021.03.010]
LUO Chao,GE Ming-jian.Research Status of Stem Pleural Metastasis of Non-small Cell Lung Cancer[J].Journal of Medical Information,2021,34(03):31.[doi:10.3969/j.issn.1006-1959.2021.03.010]
[4]苏 凝,樊利萍,秦丽丽,等.恩度联合顺铂胸腔内灌注治疗非小细胞肺癌恶性胸腔积液的疗效[J].医学信息,2021,34(11):155.[doi:10.3969/j.issn.1006-1959.2021.11.043]
SU Ning,FAN Li-ping,QIN Li-li,et al.Efficacy of Endu Combined with Cisplatin Intrapleural Perfusion in the Treatment of Non-small Cell Lung Cancer with Malignant Pleural Effusion[J].Journal of Medical Information,2021,34(03):155.[doi:10.3969/j.issn.1006-1959.2021.11.043]
[5]王会敏,徐 克,穆 红.恩度联合顺铂局部治疗对非小细胞肺癌合并恶性胸腔积液肿瘤标志物的影响[J].医学信息,2021,34(16):106.[doi:10.3969/j.issn.1006-1959.2021.16.028]
WANG Hui-min,XU Ke,MU Hong.Effect of Endo and Cisplatin Local Therapy on Tumor Markers of Non-small Cell Lung Cancer with Malignant Pleural Effusion[J].Journal of Medical Information,2021,34(03):106.[doi:10.3969/j.issn.1006-1959.2021.16.028]